mitoxantrone has been researched along with Melanoma in 33 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melphalan administered by isolated hyperthermic perfusion of the affected limb is an accepted treatment for malignant melanoma of the extremities." | 9.08 | Isolated hyperthermic perfusion with mitoxantrone of melphalan in malignant melanoma of the limb. ( Huber, PM; Huber, R; Krüger, I; Kuper, K; Pichlmaier, H, 1995) |
| " In this in vitro study we tried to reveal the anticancer properties of CBD in malignant melanoma cell lines (SK-MEL 28, A375, FM55P and FM55M2) administered alone, as well as in combination with mitoxantrone (MTX) or cisplatin (CDDP)." | 8.12 | Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis. ( Drozd, M; Florek-Łuszczki, M; Marzęda, P; Wróblewska-Łuczka, P; Załuska-Ogryzek, K; Łuszczki, JJ, 2022) |
| " The aim of this study was to investigate the cytotoxic and anti-proliferative effects of arvanil and olvanil when administered alone and in combination with cisplatin (CDDP) and mitoxantrone (MTX), using various primary (A375, FM55P) and metastatic (SK-MEL 28, FM55M2) human malignant melanoma cell lines." | 8.12 | Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis. ( Drozd, M; Florek-Łuszczki, M; Góralczyk, A; Marzęda, P; Wróblewska-Łuczka, P; Łuszczki, JJ, 2022) |
| "This study evaluated the effects of mitoxantrone (MX), an antitumor agent, as a sensitizer to both photodynamic and radiation therapy in DFW human melanoma cells." | 7.79 | Photosensitizing and radiosensitizing effects of mitoxantrone: combined chemo-, photo-, and radiotherapy of DFW human melanoma cells. ( Ahmadi, A; Bahreyni-Toosi, MH; Montazerabadi, AR; Sazgarnia, A, 2013) |
| "Twenty-nine patients with metastatic malignant melanoma without prior chemotherapy and 36 patients refractory to prior chemotherapy received mitoxantrone (5 mg/m2/week)." | 7.67 | Mitoxantrone in malignant melanoma. ( Bartolucci, A; Gams, R; Presant, CA, 1984) |
| "The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial of Dihydroxyanthracenedione (DHAD, Mitoxantrone, NSC 301739) in 28 patients with advanced malignant melanoma, none of whom had received prior cytotoxic chemotherapy." | 7.67 | A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma. ( Arseneau, JC; Borden, EC; Schoenfeld, DA, 1986) |
| "In a phase II study 20 patients with measurable metastatic melanoma were treated with amsacrine 120 mg/m2 every 3 weeks." | 7.67 | Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene. ( Bishop, J; Coates, AS; Mann, GJ; Raghavan, D, 1986) |
| "(1) Malignant melanomas are dangerous skin cancers, and the treatment of melanomas with various cytostatic drugs often causes side effects and after their prolonged use resistance to these drugs appears." | 5.91 | Synergy, Additivity and Antagonism between Esculetin and Six Commonly Used Chemotherapeutics in Various Malignant Melanoma Cell Lines-An Isobolographic Analysis. ( Góralczyk, A; Wróblewska-Łuczka, P; Łuszczki, JJ, 2023) |
| "Malignant melanoma is a skin cancer characterized by rapid development, poor prognosis and high mortality." | 5.72 | Fraxetin Interacts Additively with Cisplatin and Mitoxantrone, Antagonistically with Docetaxel in Various Human Melanoma Cell Lines-An Isobolographic Analysis. ( Góralczyk, A; Grabarska, A; Marzęda, P; Wróblewska-Łuczka, P; Łuszczki, JJ, 2022) |
| "Mitoxantrone (MTO) was topically applied for melanoma therapy using an MTO ethosome gel." | 5.42 | Improved anti-melanoma effect of a transdermal mitoxantrone ethosome gel. ( Du, L; Fu, G; Jin, Y; Li, Y; Yu, X, 2015) |
| "Anacardic acid is a potent epigenetic agent with anticancer activity." | 5.40 | Anacardic acid enhances the anticancer activity of liposomal mitoxantrone towards melanoma cell lines - in vitro studies. ( Filipczak, N; Gubernator, J; Kozubek, A; Legut, M; Lipka, D; Piwoni, A, 2014) |
| " In this in vitro study we tried to reveal the anticancer properties of CBD in malignant melanoma cell lines (SK-MEL 28, A375, FM55P and FM55M2) administered alone, as well as in combination with mitoxantrone (MTX) or cisplatin (CDDP)." | 4.12 | Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis. ( Drozd, M; Florek-Łuszczki, M; Marzęda, P; Wróblewska-Łuczka, P; Załuska-Ogryzek, K; Łuszczki, JJ, 2022) |
| " The aim of this study was to investigate the cytotoxic and anti-proliferative effects of arvanil and olvanil when administered alone and in combination with cisplatin (CDDP) and mitoxantrone (MTX), using various primary (A375, FM55P) and metastatic (SK-MEL 28, FM55M2) human malignant melanoma cell lines." | 4.12 | Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis. ( Drozd, M; Florek-Łuszczki, M; Góralczyk, A; Marzęda, P; Wróblewska-Łuczka, P; Łuszczki, JJ, 2022) |
| "This study evaluated the effects of mitoxantrone (MX), an antitumor agent, as a sensitizer to both photodynamic and radiation therapy in DFW human melanoma cells." | 3.79 | Photosensitizing and radiosensitizing effects of mitoxantrone: combined chemo-, photo-, and radiotherapy of DFW human melanoma cells. ( Ahmadi, A; Bahreyni-Toosi, MH; Montazerabadi, AR; Sazgarnia, A, 2013) |
| "Transdermal delivery of mitoxantrone liposomes could be a potential therapy for cutaneous malignant melanoma." | 3.73 | [Preparation of mitoxantrone liposomes and study on its in vivo distribution in rats after transdermal delivery]. ( Chen, T; Hou, SX; Sun, YY; Zheng, Y, 2006) |
| "The clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg were studied in five patients exhibiting solitary, localized malignant melanoma." | 3.68 | Clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg. ( Bode, U; Ghussen, F; Krüger, I; Nagel, JD, 1991) |
| "Twenty-nine patients with metastatic malignant melanoma without prior chemotherapy and 36 patients refractory to prior chemotherapy received mitoxantrone (5 mg/m2/week)." | 3.67 | Mitoxantrone in malignant melanoma. ( Bartolucci, A; Gams, R; Presant, CA, 1984) |
| "In a phase II study 20 patients with measurable metastatic melanoma were treated with amsacrine 120 mg/m2 every 3 weeks." | 3.67 | Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene. ( Bishop, J; Coates, AS; Mann, GJ; Raghavan, D, 1986) |
| "Mitoxantrone, an anthracenedione derivative, was administered by members of the Southwest Oncology Group to thirty patients with metastatic malignant melanoma." | 3.67 | Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma. A Southwest Oncology Group pilot. ( Costanzi, JJ; Taylor, SA; Tranum, BT; Von Hoff, DD, 1985) |
| "(1) Malignant melanomas are dangerous skin cancers, and the treatment of melanomas with various cytostatic drugs often causes side effects and after their prolonged use resistance to these drugs appears." | 1.91 | Synergy, Additivity and Antagonism between Esculetin and Six Commonly Used Chemotherapeutics in Various Malignant Melanoma Cell Lines-An Isobolographic Analysis. ( Góralczyk, A; Wróblewska-Łuczka, P; Łuszczki, JJ, 2023) |
| "Malignant melanoma is a skin cancer characterized by rapid development, poor prognosis and high mortality." | 1.72 | Fraxetin Interacts Additively with Cisplatin and Mitoxantrone, Antagonistically with Docetaxel in Various Human Melanoma Cell Lines-An Isobolographic Analysis. ( Góralczyk, A; Grabarska, A; Marzęda, P; Wróblewska-Łuczka, P; Łuszczki, JJ, 2022) |
| " The affected tumors remained dormant long after dosing stopped, resulting in a prolonged progression-free survival and sustained immune surveillance of the host bearing desmoplastic melanoma." | 1.48 | Nanocarrier-Mediated Chemo-Immunotherapy Arrested Cancer Progression and Induced Tumor Dormancy in Desmoplastic Melanoma. ( Chen, F; Hou, L; Huang, L; Liu, Q; Shen, L; Wang, D; Zhang, X, 2018) |
| "Mitoxantrone (MTO) was topically applied for melanoma therapy using an MTO ethosome gel." | 1.42 | Improved anti-melanoma effect of a transdermal mitoxantrone ethosome gel. ( Du, L; Fu, G; Jin, Y; Li, Y; Yu, X, 2015) |
| "Anacardic acid is a potent epigenetic agent with anticancer activity." | 1.40 | Anacardic acid enhances the anticancer activity of liposomal mitoxantrone towards melanoma cell lines - in vitro studies. ( Filipczak, N; Gubernator, J; Kozubek, A; Legut, M; Lipka, D; Piwoni, A, 2014) |
| "Mitoxantrone has not gained widespread acceptance in the veterinary community, primarily due to its cost and single-dose packaging in a volume that exceeds the needs of the majority of veterinary cancer patients." | 1.31 | Evaluation of the in vitro cytotoxicity of mitoxantrone following repeated freeze-thaw cycles. ( Mauldin, GN; Truax, R, 2002) |
| "Choroidal melanoma has a high mortality rate and responds poorly to existing chemotherapy, but unexpected ex vivo sensitivity of a subset of these tumours to topoisomerase II inhibitors has been noted." | 1.31 | Relationship between expression of topoisomerase II isoforms and chemosensitivity in choroidal melanoma. ( Alexander, RA; Cree, IA; de Souza, L; Foss, AJ; Hickson, ID; Hungerford, JL; Myatt, N; Neale, MH; Satherley, K, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (33.33) | 18.7374 |
| 1990's | 3 (9.09) | 18.2507 |
| 2000's | 3 (9.09) | 29.6817 |
| 2010's | 9 (27.27) | 24.3611 |
| 2020's | 7 (21.21) | 2.80 |
| Authors | Studies |
|---|---|
| Zee-Cheng, RK | 3 |
| Podrebarac, EG | 1 |
| Menon, CS | 1 |
| Cheng, CC | 3 |
| Mathew, AE | 1 |
| Xu, PL | 1 |
| Northcutt, RV | 1 |
| Marzęda, P | 5 |
| Wróblewska-Łuczka, P | 7 |
| Drozd, M | 4 |
| Florek-Łuszczki, M | 4 |
| Załuska-Ogryzek, K | 1 |
| Łuszczki, JJ | 7 |
| Góralczyk, A | 6 |
| Grabarska, A | 1 |
| Pfeifer, V | 1 |
| Weber, H | 1 |
| Wang, Y | 1 |
| Schlesinger, M | 1 |
| Gorzelanny, C | 1 |
| Bendas, G | 1 |
| Liu, H | 1 |
| Kuang, X | 1 |
| Zhang, Y | 1 |
| Ye, Y | 1 |
| Li, J | 1 |
| Liang, L | 1 |
| Xie, Z | 1 |
| Weng, L | 1 |
| Guo, J | 1 |
| Li, H | 1 |
| Ma, F | 1 |
| Chen, X | 2 |
| Zhao, S | 1 |
| Su, J | 1 |
| Yang, N | 1 |
| Fang, F | 1 |
| Xie, Y | 1 |
| Tao, J | 1 |
| Zhang, J | 1 |
| Chen, M | 1 |
| Peng, C | 1 |
| Sun, L | 1 |
| Zhang, X | 2 |
| Liu, J | 1 |
| Han, L | 1 |
| Xu, X | 1 |
| Hung, MC | 1 |
| Liu, Q | 1 |
| Chen, F | 1 |
| Hou, L | 1 |
| Shen, L | 1 |
| Wang, D | 1 |
| Huang, L | 1 |
| Imanparast, A | 1 |
| Bakhshizadeh, M | 2 |
| Salek, R | 1 |
| Sazgarnia, A | 3 |
| Mohajeri, SA | 1 |
| Esmaily, H | 1 |
| Aledavood, SA | 1 |
| Varshoei Tabrizi, F | 1 |
| Seifi, M | 1 |
| Hadizadeh, F | 1 |
| Legut, M | 1 |
| Lipka, D | 1 |
| Filipczak, N | 1 |
| Piwoni, A | 1 |
| Kozubek, A | 1 |
| Gubernator, J | 1 |
| Yu, X | 2 |
| Du, L | 2 |
| Zhu, L | 1 |
| Liu, X | 1 |
| Zhang, B | 1 |
| Fu, G | 2 |
| Jin, Y | 2 |
| Li, Z | 1 |
| Zhang, FL | 1 |
| Pan, LL | 1 |
| Zhu, XL | 1 |
| Zhang, ZZ | 1 |
| Li, Y | 1 |
| Spugnini, EP | 1 |
| Fanciulli, M | 1 |
| Citro, G | 1 |
| Baldi, A | 1 |
| Montazerabadi, AR | 1 |
| Bahreyni-Toosi, MH | 1 |
| Ahmadi, A | 1 |
| Mauldin, GN | 1 |
| Truax, R | 1 |
| Chen, T | 1 |
| Hou, SX | 1 |
| Sun, YY | 1 |
| Zheng, Y | 1 |
| Alberts, DS | 1 |
| Peng, YM | 1 |
| Leigh, S | 1 |
| Davis, TP | 1 |
| Woodward, DL | 1 |
| Presant, CA | 1 |
| Gams, R | 1 |
| Bartolucci, A | 1 |
| Fujimoto, S | 1 |
| Ogawa, M | 1 |
| Huber, R | 1 |
| Krüger, I | 2 |
| Kuper, K | 1 |
| Huber, PM | 1 |
| Pichlmaier, H | 1 |
| Kirshenbaum, MR | 1 |
| Chen, SF | 1 |
| Behrens, CH | 1 |
| Papp, LM | 1 |
| Stafford, MM | 1 |
| Sun, JH | 1 |
| Behrens, DL | 1 |
| Fredericks, JR | 1 |
| Polkus, ST | 1 |
| Sipple, P | 1 |
| Satherley, K | 1 |
| de Souza, L | 1 |
| Neale, MH | 1 |
| Alexander, RA | 1 |
| Myatt, N | 1 |
| Foss, AJ | 1 |
| Hungerford, JL | 1 |
| Hickson, ID | 1 |
| Cree, IA | 1 |
| Nagel, JD | 1 |
| Ghussen, F | 1 |
| Bode, U | 1 |
| White, RJ | 1 |
| Durr, FE | 1 |
| Matuszyk, J | 1 |
| Kuśnierczyk, H | 1 |
| Radzikowski, C | 1 |
| Arseneau, JC | 1 |
| Schoenfeld, DA | 1 |
| Borden, EC | 1 |
| Coates, AS | 1 |
| Bishop, J | 1 |
| Mann, GJ | 1 |
| Raghavan, D | 1 |
| Taylor, SA | 1 |
| Tranum, BT | 1 |
| Von Hoff, DD | 1 |
| Costanzi, JJ | 1 |
1 review available for mitoxantrone and Melanoma
| Article | Year |
|---|---|
Preclinical models in electrochemotherapy: the role of veterinary patients.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 2012 |
1 trial available for mitoxantrone and Melanoma
| Article | Year |
|---|---|
Isolated hyperthermic perfusion with mitoxantrone of melphalan in malignant melanoma of the limb.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regiona | 1995 |
31 other studies available for mitoxantrone and Melanoma
| Article | Year |
|---|---|
Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Colonic Neoplasms; Leukemia L1210; Leukemia, Experim | 1979 |
Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Leukemia, Experimental; Melanoma; Mice; Neoplasms, E | 1978 |
Structural modification study of mitoxantrone (DHAQ). Chloro-substituted mono- and bis[(aminoalkyl)amino]anthraquinones.
Topics: Animals; Anthraquinones; Leukemia L1210; Leukemia P388; Melanoma; Mitoxantrone; Structure-Activity R | 1987 |
Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Cannabidiol; Cell Line; Cisplatin; Humans; Melanoma; Mitoxantrone | 2022 |
Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Humans; Melanoma; Mitoxantrone | 2022 |
Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Humans; Melanoma; Mitoxantrone | 2022 |
Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Humans; Melanoma; Mitoxantrone | 2022 |
Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Humans; Melanoma; Mitoxantrone | 2022 |
Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Humans; Melanoma; Mitoxantrone | 2022 |
Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Humans; Melanoma; Mitoxantrone | 2022 |
Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Humans; Melanoma; Mitoxantrone | 2022 |
Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Humans; Melanoma; Mitoxantrone | 2022 |
Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Humans; Melanoma; Mitoxantrone | 2022 |
Fraxetin Interacts Additively with Cisplatin and Mitoxantrone, Antagonistically with Docetaxel in Various Human Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cisplatin; Docetaxel; Humans; Melanoma; Melanoma | 2022 |
Exostosin 1 Knockdown Induces Chemoresistance in MV3 Melanoma Cells by Upregulating JNK and MEK/ERK Signaling.
Topics: Antineoplastic Agents; Doxorubicin; Drug Resistance, Neoplasm; Heparan Sulfate Proteoglycans; Humans | 2023 |
Synergy, Additivity and Antagonism between Esculetin and Six Commonly Used Chemotherapeutics in Various Malignant Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Cisplatin; Cytostatic A | 2023 |
Daphnetin, a Coumarin with Anticancer Potential against Human Melanoma: In Vitro Study of Its Effective Combination with Selected Cytostatic Drugs.
Topics: Cisplatin; Coumarins; Cytostatic Agents; Docetaxel; Epirubicin; Humans; Melanoma; Melanoma, Cutaneou | 2023 |
ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.
Topics: Activating Transcription Factor 3; Adenosine A1 Receptor Antagonists; Adult; Aged; Animals; Antineop | 2020 |
Nanocarrier-Mediated Chemo-Immunotherapy Arrested Cancer Progression and Induced Tumor Dormancy in Desmoplastic Melanoma.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Progressio | 2018 |
Pegylated hollow gold-mitoxantrone nanoparticles combining photodynamic therapy and chemotherapy of cancer cells.
Topics: Cell Death; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Drug Liberation; Drug Stability; | 2018 |
Utilizing photosensitizing and radiosensitizing properties of TiO
Topics: Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dose-Response Relationship, Drug; Fibrosarcoma; | 2019 |
Anacardic acid enhances the anticancer activity of liposomal mitoxantrone towards melanoma cell lines - in vitro studies.
Topics: Anacardic Acids; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Di | 2014 |
Melanoma therapy with transdermal mitoxantrone cubic phases.
Topics: Administration, Cutaneous; Antineoplastic Agents; Glycerides; Humans; Immunohistochemistry; Melanoma | 2016 |
Preparation and characterization of injectable Mitoxantrone poly (lactic acid)/fullerene implants for in vivo chemo-photodynamic therapy.
Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Combined Modality Therapy; Drug Carriers; | 2015 |
Improved anti-melanoma effect of a transdermal mitoxantrone ethosome gel.
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents; Gels; Male; Melanoma; Mice; Mice, Inbred | 2015 |
Photosensitizing and radiosensitizing effects of mitoxantrone: combined chemo-, photo-, and radiotherapy of DFW human melanoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Humans; Melanoma; | 2013 |
Evaluation of the in vitro cytotoxicity of mitoxantrone following repeated freeze-thaw cycles.
Topics: Animals; Antineoplastic Agents; Dogs; Dose-Response Relationship, Drug; Drug Stability; Freezing; Me | 2002 |
[Preparation of mitoxantrone liposomes and study on its in vivo distribution in rats after transdermal delivery].
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents; Female; Liposomes; Melanoma; Microscopy, | 2006 |
Disposition of mitoxantrone in patients.
Topics: Adenocarcinoma; Anthraquinones; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Evaluation; Fe | 1983 |
Mitoxantrone in malignant melanoma.
Topics: Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; | 1984 |
Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics.
Topics: Animals; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents; Drug Resistance; Female | 1982 |
(R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Division; Clinical Trials, Phase I as Topic; Colonic | 1994 |
Relationship between expression of topoisomerase II isoforms and chemosensitivity in choroidal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic A | 2000 |
Clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg.
Topics: Adult; Chemotherapy, Cancer, Regional Perfusion; Female; Humans; Hyperthermia, Induced; Leg; Male; M | 1991 |
Development of mitoxantrone.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Cell Line; Chemistry, Pharmaceutical; Colonic Neopla | 1985 |
Biological evaluation of mitoxantrone dihydrochloride synthesized by a new method. II. Comparison of Now 85/34 and Novantrone (Lederle) acute toxicity and antitumor activity.
Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Leukemia, Experimental; Male; Mela | 1989 |
A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma.
Topics: Anthraquinones; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Female; Humans | 1986 |
Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene.
Topics: Aminoacridines; Amsacrine; Anthracenes; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Fema | 1986 |
Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma. A Southwest Oncology Group pilot.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Humans; Infusions, Pare | 1985 |